Attention-deficit/hyperactivity disorder (ADHD) often requires long-term pharmacologic management in childhood, with methylphenidate (MPH) as a first-line stimulant. However, concerns persist regarding the potential effects of both ADHD and its treatment on physical growth trajectories and later-life health. A large retrospective cohort study published in JAMA Network Open examined associations between childhood ADHD diagnoses, cumulative MPH use, and adult body mass index (BMI) and height at ages 20–25 years.